Recro Pharma (REPH) Misses Q1 EPS by 30c, Revenues Beat; Offers FY20 Revenue Guidance Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Recro Pharma (REPH) Misses Q1 EPS by 30c, Revenues Beat; Offers FY20 Revenue Guidance Below Consensus

Recro Reports First Quarter 2020 Financial Results and Provides Update on COVID-19 Response and Impact

May 11, 2020 7:01 AM EDT

Company Generates $21.8 Million in First Quarter 2020 Revenues

Revises Annual Revenue Guidance for 2020

MALVERN, Pa., May 11, 2020 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq: REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for the development, formulation, regulatory support, manufacturing and packaging of oral solid dose drug products, today reported financial results for the three months ended March 31, 2020.

In this challenging and unprecedented time, U.S. pharmaceutical product manufacturing has never been more essential,... More